https://scholars.lib.ntu.edu.tw/handle/123456789/194892
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor | 小兒科 | en |
dc.contributor.author | Liang, D-C | en |
dc.contributor.author | Hung, I-J | en |
dc.contributor.author | Yang, C-P | en |
dc.contributor.author | Lin, K-H | en |
dc.contributor.author | Chen, J-S | en |
dc.contributor.author | Hsiao, T-C | en |
dc.contributor.author | Chang, T-T | en |
dc.contributor.author | Pui, C-H | en |
dc.contributor.author | Lee, C-H | en |
dc.contributor.author | Lin, K-S | en |
dc.creator | 林凱信 | zh-tw |
dc.creator | Liang, D-C; Hung, I-J; Yang, C-P; Lin, K-H; Chen, J-S; Hsiao, T-C; Chang, T-T; Pui, C-H; Lee, C-H; Lin, K-S | en |
dc.date | 1999 | en |
dc.date.accessioned | 2008-12-29T06:04:44Z | - |
dc.date.accessioned | 2018-07-11T17:54:23Z | - |
dc.date.available | 2008-12-29T06:04:44Z | - |
dc.date.available | 2018-07-11T17:54:23Z | - |
dc.date.issued | 1999 | - |
dc.identifier.uri | http://ntur.lib.ntu.edu.tw//handle/246246/94784 | - |
dc.description.abstract | The relative efficacy and toxicity of E. coli L-asparaginase and epidoxorubicin used in remission induction therapy for childhood acute lymphoblastic leukemia (ALL) were assessed in a randomized trial conducted in Taiwan. All patients had standard-risk ALL, defined as a leukocyte count < 10 x 10(9) /l and were aged between 1 and 2 or 7 and 10 years, or a leukocyte count <50 x 10(9)/l and were aged between 2 and 7 years, without evidence of a T cell or mature B cell immunophenotype, central nervous system leukemia or expression of two or more myeloid-associated antigens. Ninety-three patients were randomized to receive E. coli L- asparaginase at 10 000 IU/m(2) thrice weekly for nine doses and 108 to receive epidoxorubicin at 20 mg/m(2) weekly for two doses during remission induction with daily prednisolone , weekly vincristine and, on day 22, a dose of etoposide plus cytarabine. Patients treated with L-asparaginase had a significantly higher rate of fatal infection with or without hemorrhage than did those who received epidoxorubicin during remission induction (six of 93 vs none of 108, P = 0. 009), resulting in a lower rate of complete remission in the former group (93.6 vs 99.1%, P = 0.05). In addition, patients treated with L-asparaginase had a higher frequency of hyperglycemia and hypoalbuminemia. The overall rate of event-free survival was lower in patients treated with L- asparaginase than in other patients (P = 0.06); estimated 3- year rates were 72% (95% confidence interval, 55-89%) and 87.2% (78-96%), respectively. We conclude that L- asparaginase(Leunase) given at 10 000 IU/m(2) for nine doses was poorly tolerated and resulted in excessive toxicity, both through its effects as a single agent and possibly through potentiation of etoposide. | en |
dc.language | en-us | en |
dc.language.iso | en_US | - |
dc.relation | LEUKEMIA v.13 n.2 pp.155-160 | en |
dc.relation.ispartof | LEUKEMIA | - |
dc.subject | acute lymphoblastic leukemia | en |
dc.subject | L-asparaginase | en |
dc.subject | remission induction | en |
dc.subject | ACUTE LYMPHOCYTIC-LEUKEMIA | en |
dc.subject | CHEMOTHERAPY | en |
dc.subject | CHILDREN | en |
dc.title | Unexpected Mortality from the Use of E-Coli L-Asparaginase during Remission Induction Therapy for Childhood Acute Lymphoblastic Leukemia: A Report from the Taiwan Pediatric Oncology Group | en |
dc.type | journal article | en |
dc.relation.pages | 155-160 | - |
dc.relation.journalvolume | v.13 | - |
dc.relation.journalissue | n.2 | - |
item.languageiso639-1 | en_US | - |
item.openairetype | journal article | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。